Clinical Trial Update: Study to Evaluate the Safety and Tolerability of Two Doses of Rilonacept in Pediatric Subjects With Active Systemic Juvenile Idiopathic Arthritis (SJIA) [Phase 1]

View source ↗

Summary

A Phase 1 study evaluating the safety and tolerability of two doses of rilonacept in pediatric patients with active systemic juvenile idiopathic arthritis has c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Juvenile Idiopathic Arthritis

Drugs mentioned

• Arcalyst (rilonacept)

Snippet

Sponsor: Regeneron Pharmaceuticals | Conditions: Systemic Juvenile Idiopathic Arthritis | Phase 1 | Status: COMPLETED